[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615111":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":48,"locations":56,"responsibleParty":172,"collaborators":36,"id":174,"slug":36,"hasResults":175,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":36,"eligibilityCriteria":179,"healthyVolunteers":175,"sex":180,"minAge":181,"maxAge":36,"enrollmentInfo":182,"targetDuration":36,"studyType":185,"phases":186,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":59,"whyStopped":36,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"GVV858 Single Agent (Arm A)","EXPERIMENTAL","Phase I",[13],"Drug: GVV858",{"label":15,"type":10,"description":11,"interventionNames":16},"GVV858 in combination with fulvestrant (Arm B)",[13,17],"Drug: Fulvestrant",{"label":19,"type":10,"description":11,"interventionNames":20},"GVV858 in combination with letrozole (Arm C)",[13,21],"Drug: Letrozole",{"label":23,"type":10,"description":24,"interventionNames":25},"GVV858 in combination with fulvestrant (Arm D)","Phase II, recommended dose regimen 1",[13,17],{"label":27,"type":10,"description":28,"interventionNames":29},"GVV858 in combination with fulvestrant (Arm E)","Phase II, recommended dose regimen 2, optional dose optimization",[13,17],[31,37,43],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","GVV858","Experimental",[9,15,23,27,19],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Fulvestrant","Approved medication",[15,23,27],[42],"Faslodex",{"type":32,"name":44,"description":39,"armGroupLabels":45,"otherNames":46},"Letrozole",[19],[47],"Femara",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":36,"email":53},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":50,"role":51,"phone":55,"phoneExt":36,"email":36},"+41613241111",[57,77,87,96,106,114,124,129,138,146,155,163],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Tennessee Oncology PLLC","RECRUITING","Nashville","Tennessee","37203","United States",{"type":65,"coordinates":66},"Point",[67,68],-86.78444,36.16589,{"lat":68,"lon":67},[71,74],{"name":72,"role":51,"phone":36,"phoneExt":36,"email":73},"Caitlin J Pecknold","cpecknold@tnonc.com",{"name":75,"role":76,"phone":36,"phoneExt":36,"email":36},"Jeffery Russell","PRINCIPAL_INVESTIGATOR",{"facility":78,"status":59,"city":79,"state":36,"zip":80,"country":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":36},"Novartis Investigative Site","Olomouc","779 00","Czechia",{"type":65,"coordinates":83},[84,85],17.25175,49.59552,{"lat":85,"lon":84},{"facility":78,"status":59,"city":88,"state":36,"zip":89,"country":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":36},"Odense C","5000","Denmark",{"type":65,"coordinates":92},[93,94],10.39538,55.40841,{"lat":94,"lon":93},{"facility":78,"status":59,"city":97,"state":98,"zip":99,"country":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":36},"Jena","Thuringia","07740","Germany",{"type":65,"coordinates":102},[103,104],11.5899,50.92878,{"lat":104,"lon":103},{"facility":78,"status":59,"city":107,"state":36,"zip":108,"country":100,"cosmosGeoPoint":109,"geoPoint":113,"contacts":36},"Essen","45147",{"type":65,"coordinates":110},[111,112],7.01228,51.45657,{"lat":112,"lon":111},{"facility":78,"status":59,"city":115,"state":116,"zip":117,"country":118,"cosmosGeoPoint":119,"geoPoint":123,"contacts":36},"Milan","MI","20162","Italy",{"type":65,"coordinates":120},[121,122],12.59836,42.78235,{"lat":122,"lon":121},{"facility":78,"status":59,"city":115,"state":36,"zip":125,"country":118,"cosmosGeoPoint":126,"geoPoint":128,"contacts":36},"20141",{"type":65,"coordinates":127},[121,122],{"lat":122,"lon":121},{"facility":78,"status":59,"city":130,"state":36,"zip":131,"country":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":36},"Kyoto","6068507","Japan",{"type":65,"coordinates":134},[135,136],135.75385,35.02107,{"lat":136,"lon":135},{"facility":78,"status":59,"city":139,"state":36,"zip":140,"country":139,"cosmosGeoPoint":141,"geoPoint":145,"contacts":36},"Singapore","168583",{"type":65,"coordinates":142},[143,144],103.85007,1.28967,{"lat":144,"lon":143},{"facility":78,"status":59,"city":147,"state":36,"zip":148,"country":149,"cosmosGeoPoint":150,"geoPoint":154,"contacts":36},"Barcelona","08035","Spain",{"type":65,"coordinates":151},[152,153],2.15899,41.38879,{"lat":153,"lon":152},{"facility":78,"status":59,"city":156,"state":36,"zip":157,"country":149,"cosmosGeoPoint":158,"geoPoint":162,"contacts":36},"Madrid","28041",{"type":65,"coordinates":159},[160,161],-3.70256,40.4165,{"lat":161,"lon":160},{"facility":78,"status":59,"city":164,"state":36,"zip":165,"country":166,"cosmosGeoPoint":167,"geoPoint":171,"contacts":36},"Taipei","10002","Taiwan",{"type":65,"coordinates":168},[169,170],121.52639,25.05306,{"lat":170,"lon":169},{"type":173,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100615111",false,"NCT07288359","Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+\u002FHER2- Breast Cancer and Other Advanced Solid Tumors","An Open-label, Multi-center, Phase I\u002FII Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Patients with one of the following histologically or cytologically confirmed advanced cancers:\n\nPhase I (patients with one of the following cancers, from whom no standard therapy is available or appropriate in the judgment of the investigator):\n\n* HR+\u002FHER2- advanced breast cancer (aBC) with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4\u002F6i and at least one additional line of systemic therapy for metastatic disease.\n* Locally advanced or metastatic cancer with a CCNE1 amplification. For dose expansion only: no more than 3 prior lines of therapy for advanced or metastatic disease.\n* Metastatic castration-resistant prostate adenocarcinoma, with no documented neuroendocrine component, castrate level of testosterone, and no more than 3 prior lines of systemic therapy for metastatic disease.\n\nPhase II:\n\n* HR+\u002FHER2- aBC with disease progression on or after an endocrine therapy in combination, with a CDK4\u002F6 inhibitor for advanced disease with no more than 2 lines of endocrine therapy and no prior cytotoxic chemotherapy or antibody-drug-conjugate for advanced disease.\n\n  \\- Measurable disease as determined by RECIST v1.1.\n* BC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment.\n* metastatic Castration-Resistant Prostate Cancer (mCRPC) only: If no measurable disease is present per PCWG3 modified RECIST, then at least 1 metastatic lesion must be present on bone scan imaging.\n\nExclusion Criteria:\n\n* Patients with inadequate bone marrow and\u002For organ functions with out-of-range laboratory values.\n* Clinically significant, uncontrolled heart disease and\u002For cardiac repolarization abnormality including myocardial infarction (MI), coronary artery bypass graft (CABG), long QT syndrome, or risk factors for Torsades de Pointes (TdP).\n* Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local therapy or increasing doses of corticosteroids within 2 weeks prior to study entry.\n* Patients with symptomatic visceral disease, including visceral crisis.\n* For patients with BC: Patient is concurrently using hormone replacement therapy.\n* Women of childbearing potential who are unwilling to use highly effective contraception methods, pregnant or nursing women.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":183,"type":184},205,"ESTIMATED","INTERVENTIONAL",[187,188],"PHASE1","PHASE2","Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization\u002Frecommended dose for further clinical evaluation.\n\nPhase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative (HR+\u002FHER2-) advanced breast cancer.",[191,192,193],"Advanced HR+\u002FHER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors","Metastatic Castration-resistant Prostate Cancer",[33,38,44,195,196,197],"Breast Cancer","CCNE1 amplification","Prostate Cancer","2026-06-29",{"date":200,"type":201},"2026-06-30","ACTUAL",{"date":203,"type":201},"2025-12-29",{"date":205,"type":184},"2031-05-09",{"name":50,"class":6},12]